Consolidating evidence on the role of insulin resistance in major depressive disorder

• Published in: Current opinion in psychiatry Vol. 37; no. 1; p. 23
• Main Authors: Krupa, Anna Julia, Dudek, Dominika, Siwek, Marcin
• Format: Journal Article
• Language: English
• Published: United States 01.01.2024
• Subjects: Antidepressive Agents - therapeutic use; Depression; Depressive Disorder, Major - drug therapy; Diabetes Mellitus, Type 2 - complications; Humans; Insulin Resistance; Insulins - therapeutic use
• DOI: 10.1097/YCO.0000000000000905

The circular interactions between type 2 diabetes (TMD2) and major depressive disorder (MDD) are well documented but the understanding of their mechanisms has only recently gained more clarity. Latest research indicates, that the association between TMD2 and MDD is largely mediated by insulin resistance (IR). A metabolic subtype of MDD can be distinguished from other MDD subpopulations, that is characterized by predominantly atypical clinical presentation, IR and different responsiveness to antidepressant interventions. IR is a predictor of nonresponse to some antidepressants. The IR seems to be a state-marker of clinical or subclinical depression and the relationship between IR and MDD varies between sexes and ethnicities. Insulin has a direct impact on the monoaminergic systems known to underlie MDD symptoms: serotoninergic and dopaminergic, which are dysregulated in IR subjects. Several trials assessed the efficacy of insulin-sensitizing drugs in MDD with mixed results for metformin and more consistent evidence for pioglitazone and lifestyle intervention/physical activity. Recently published data suggest a significant role of IR in the clinical presentation, pathophysiology and treatment response in MDD. Further research of IR in MDD and integration of existing data into clinical practice are needed.